Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7847 Phase 3 study for prevention of chemotherapy-induced nausea and vomiting
jRCT2080220800Phase 3
- Sponsor
- Ono Pharmaceutical
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced nausea and vomiting (CINV) comparing ONO-7847 150 mg IV with Placebo IV (2 arms).
02
Drugs
fosaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on jRCT2080220800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220800.